Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Non-Current Assets (2016 - 2026)

Akebia Therapeutics has reported Other Non-Current Assets over the past 11 years, most recently at $59.7 million for Q4 2025.

  • Quarterly Other Non-Current Assets rose 59.67% to $59.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $59.7 million through Dec 2025, up 59.67% year-over-year, with the annual reading at $59.7 million for FY2025, 59.67% up from the prior year.
  • Other Non-Current Assets was $59.7 million for Q4 2025 at Akebia Therapeutics, up from $40.5 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $69.6 million in Q3 2021 and troughed at $3.3 million in Q2 2023.
  • The 5-year median for Other Non-Current Assets is $36.2 million (2022), against an average of $31.7 million.
  • Year-over-year, Other Non-Current Assets tumbled 90.42% in 2023 and then surged 602.59% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $50.4 million in 2021, then tumbled by 89.35% to $5.4 million in 2022, then surged by 131.25% to $12.4 million in 2023, then surged by 200.87% to $37.4 million in 2024, then soared by 59.67% to $59.7 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Other Non-Current Assets are $59.7 million (Q4 2025), $40.5 million (Q3 2025), and $44.2 million (Q2 2025).